From risk profiling to rural-ready action: Making multidrug-resistant organism prediction implementable in neurosurgical care

FIRST, PREDICTION MUST BE EXPLICITLY CONNECTED TO EARLY CLINICAL DECISIONS

Prediction becomes operational when it states what a “high-risk” label should change at the bedside: Empiric therapy pathways, isolation/cohorting, device management, and diagnostic stewardship triggers. EVDs and other devices are major interface points; standardized insertion-and-maintenance bundles have been shown to reduce infection rates when compliance is monitored, and low-value manipulations are minimized.^[2-5] Linking prediction thresholds to a device-focused action set would convert risk profiling into prevention.

SECOND, STEWARDSHIP EQUITY DEPENDS ON SYNDROME-SPECIFIC PHENOTYPING RATHER THAN ORGANISM LABELS ALONE

Stewardship equity also depends on syndrome-specific phenotyping rather than organism labels alone. Rural neurosurgical teams must distinguish colonization from infection, and couple MDRO risk to the clinical syndrome (e.g., ventriculitis/meningitis, surgical-site infection, and bloodstream infection) while accounting for device-days and recent antibiotic exposure. This reduces both undertreatment and inequitable overuse of last-line agents. Contemporary guidance emphasizes syndrome-directed, susceptibility-guided therapy supported by diagnostic stewardship.^[6-9]

THIRD, SURVEILLANCE SHOULD TRIGGER A RURAL-READY NEUROSURGICAL ANTIMICROBIAL RESISTANCE (AMR) BUNDLE WITH A MINIMUM DATASET AND OPTIONAL REMOTE SUPPORT

Surveillance should then trigger a rural-ready neurosurgical AMR bundle supported by a minimum dataset (syndrome, device type and device-days, antibiotic history, and culture timing) and standardized actions: (i) culture stewardship (avoid routine sampling), (ii) time-boxed empiric therapy with de-escalation checkpoints, (iii) device-specific prevention steps, and (iv) optional remote oversight (tele-ID/tele-pharmacy) for complex cases. Pharmacist-led stewardship models have achieved measurable reductions in inappropriate antimicrobial use in neurosurgical Intensive Care Units and may be adaptable for rural networks.^[7]

Finally, local neurosurgical MDRO data should be interpreted within the global AMR burden, which disproportionately stresses low-capacity systems.^[10] A prospective, multicenter extension that links prediction thresholds to explicit actions (and audits adherence) would strengthen the paper’s translational value and support rural implementation.